Active Tuberculosis Is Associated with Worse Clinical Outcomes in HIV-Infected African Patients on Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Siika, Abraham M ^a,b   Yiannoutsos, Constantin T ^b,c   Wools Kaloustian, Kara K ^b,c   Musick, Beverly S ^b,c   Mwangi, Ann W ^b,d   Diero, Lameck O ^a,b   Kimaiyo, Sylvester N ^a,b   Tierney, William M ^b,c,e   Carter, Jane E ^b,e  

^a MOI UNIVERSITY   (Kenya)

^b ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN; ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; ETHNIC GROUP; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KENYA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; SPUTUM SMEAR; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS; WEIGHT GAIN;

EID: 84871763520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053022     Document Type: Article

References (42)

1. World Health Organization (2012) Global tuberculosis Report 2012. Available: http://www.who.int/tb/publications/global_report/2010/en/index.html.
2. UNAIDS (2010) UNAIDS report on the global AIDS epidemic 2010. Available: http://www.unaids.org/documents/20101123_GlobalReport_Chap2_em.pdf.
3. Division of Leprosy Tuberculosis and Lung disease (2012) Annual Report 2010. In. Nairobi, Kenya: Ministry of Public Health and Sanitation, Government of Kenya. Available: http://www.nltp.co.ke/docs/Annual_Report_2010.pdf.
4. Getahun H, Gunneberg C, Granich R, Nunn P, (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50 (Suppl 3):: S201-S207.
5. Corbett EL, De Cock KM, (2001) The clinical significance of interactions between HIV and TB: more questions than answers. Int J Tuberc Lung Dis 5: 205-7.
6. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, et al. (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151: 129-35.
7. Del Amo J, Malin AS, Pozniak A, De Cock KM, (1999) Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS 13: 1151-8.
8. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G, (2001) Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 5: 225-32.
9. Lopez-Gatel H, Cole SR, Margolick JB, Witt MD, Martinson J, et al. (2008) Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS 22: 1869-73.
10. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
11. Getahun H, Gunneberg C, Granich R, Nunn P, (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50 (Suppl 3):: S201-S207.
12. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ, (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4: 165-176.
13. Murray EJ, Bond VA, Marais BJ, Godfrey-Faussett P, Ayles HM, et al. (2012) High levels of vulnerability and anticipated stigma reduce the impetus for tuberculosis diagnosis in Cape Town, South Africa. Health Policy Plan. Epub ahead of print.
14. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, et al. (2010) Significant variation in presentation of pulmonary tuberculosis across a resolution of CD4 strata. Int J Tuberc Lung Dis 14: 1295-302.
15. Pitchenik A, Rubinson H, (1985) The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 131: 393-396.
16. Asimos AW, Ehrhardt J, (1996) Radiographic presentation of pulmonary tuberculosis in severely immunosuppressed HIV-seropositive patients. Am J Emerg Med 14: 359-363.
17. Chaisson R, Schecter G, Theuer C, Rutherford G, Echenberg D, et al. (1987) Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 136: 570-574.
18. Reid MJ, Shah NS, (2009) Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 9: 173-184.
19. Lawn SD, Wood R, (2011) Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 204 (Suppl 4):: S1159-S1167.
20. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
21. Ivers LC, Kendrick D, Doucette K, (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224.
22. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. N Engl J Med 362: 697-706.
23. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med 365: 1482-91.
24. Moore D, Liechty C, Ekwaru P, Were W, Mwima G, et al. (2007) Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21: 713-719.
25. Makombe SD, Jahn A, Tweya H, Chuka S, Yu JK, et al. (2007) A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. PLoS One 2: e620.
26. Einterz RM, Kimaiyo S, Mengech HN, Khwa-Otsyula BO, Esamai F, et al. (2007) Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med 82: 812-818.
27. Odhiambo J, Kizito W, Njoroge A, Wambua N, Nganga L, et al. (2008) Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis 12: 63-68.
28. Division of Leprosy Tuberculosis and Lung disease (2006) Guidelines for implementing TB-HIV collaborative activities in Kenya. What Health Care workers need to know. In. Nairobi, Kenya.
29. World Health Organization (2010) Treatment of tuberculosis: guidelines -4th edition. Geneva, Switzerland. WHO Press.
30. National AIDS and STI Control Programme (2005) Guidelines for Antiretroviral Drug Therapy in Kenya- Third Edition. Nairobi, Kenya: Ministry of Health and Sanitation.
31. Siika AM, Rotich JK, Simiyu CJ, Kigotho EM, Smith FE, et al. (2005) An electronic medical record system for ambulatory care of HIV-infected patients in Kenya. Int J Med Inform 74: 345-355.
32. Tierney WM, Rotich JK, Hannan TJ, Siika AM, Biondich PG, et al. (2007) The AMPATH medical record system: creating, implementing, and sustaining an electronic medical record system to support HIV/AIDS care in western Kenya. Stud Health Technol Inform 129: 372-376.
33. World Health Organization (2007) WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. In. Geneva: World Health Organization.
34. Fleming TR, Neaton JD, Goldman A, DeMets DL, Launer C, et al. (1995) Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 10 (Suppl 2):: S9-18.
35. Pinheiro JC, Bates DM (2000) Mixed-Effects Models in S and S-PLUS. New York: Springer.
36. R Development Core Team (2009) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
37. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, et al. (1998) Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18: 80-85.
38. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, et al. (2002) Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 230-236.
39. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, et al. (2004) Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 190: 148-155.
40. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20: 41-48.
41. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411.
42. Yiannoutsos CT, An MW, Frangakis CE, Musick BS, Braitstein P, et al. (2008) Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One 3: e3843.